首页> PloS one> Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease.

Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease.

导出 OA

翻译打印收藏纠错

第一作者： Ahmed,Al-Darraji

第一单位： Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, United States of America.

作者： Ahmed,Al-Darraji ^[1] ; Dalia,Haydar ^[2] ; Lakshman,Chelvarajan ^[1] ; Himi,Tripathi ^[1] ; Bryana,Levitan ^[1] ; Erhe,Gao ^[3] ; Vincent J,Venditto ^[2] ; John C,Gensel ^[4] ; David J,Feola ^[2] ; Ahmed,Abdel-Latif ^[5]

作者单位： Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, United States of America. ^[1] College of Pharmacy, University of Kentucky, Lexington, KY, United States of America. ^[2] The Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, United States of America. ^[3] Spinal Cord and Brain Injury Research Center, Department of Physiology, College of Medicine University of Kentucky, Lexington, KY, United States of America. ^[4] Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, United States of America.;The Lexington VA Medical Center, Lexington, KY, United States of America. ^[5]